Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence

The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Research output: Contribution to journalArticle

Abstract

Aldehyde dehydrogenase 1 (ALDH1) is a cancer stem cell (CSC) marker that is easily evaluable. The expression and clinical significance of ALDH1 in ipsilateral breast tumor recurrence (IBTR) has yet to be investigated. In the present study, the expression profile of ALDH1 and its correlation with prognosis in IBTR tissues was examined. Patients with IBTR from eight institutions were retrospectively enrolled in the study. Immunohistochemistry was used to examine ALDH1 expression patterns in the tissue specimens of primary cancers and IBTRs. ALDH1 expression levels were investigated in 182 IBTR tumors, which included cases of invasive carcinoma selected from 271 consecutive patients with IBTR. ALDH1 was expressed in 23% of the IBTR tissue samples. The rate of concordant expression between primary cancer and IBTR tissues was 68%. There was no significant association between disease-free survival (DFS) and ALDH1 expression levels in IBTR. IBTRs that expressed ALDH1 and Ki-67 had a poorer prognosis and this expression pattern was significantly associated with DFS (P=0.0073). The percentages of ALDH1 positive expression in each tissue subtype were as follows: Luminal A, 20%; luminal B, 24%; human epidermal growth factor 2 (HER2), 35%; triple-negative, 21%. There was a significant correlation between DFS and ALDH1 expression levels in HER2-type IBTR tissue specimens (P=0.034). In conclusion, it is possible that ALDH1 and Ki-67 expression levels may be useful for predicting prognosis in patients with HER2-type tumors.

Original languageEnglish
Pages (from-to)1071-1077
Number of pages7
JournalOncology Letters
Volume13
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Breast Neoplasms
Recurrence
Epidermal Growth Factor
Disease-Free Survival
aldehyde dehydrogenase 1
Neoplasms
Neoplastic Stem Cells
Immunohistochemistry
Carcinoma

Keywords

  • Aldehyde dehydrogenase 1
  • Breast cancer
  • Cancer stem cell
  • Ipsilateral breast tumor recurrence
  • Prognostic factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society (2017). Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence. Oncology Letters, 13(3), 1071-1077. https://doi.org/10.3892/ol.2016.5538

Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence. / The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

In: Oncology Letters, Vol. 13, No. 3, 01.03.2017, p. 1071-1077.

Research output: Contribution to journalArticle

The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society 2017, 'Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence', Oncology Letters, vol. 13, no. 3, pp. 1071-1077. https://doi.org/10.3892/ol.2016.5538
The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence. Oncology Letters. 2017 Mar 1;13(3):1071-1077. https://doi.org/10.3892/ol.2016.5538
The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. / Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence. In: Oncology Letters. 2017 ; Vol. 13, No. 3. pp. 1071-1077.
@article{1c173665c3034a6cbb9a3fdaba505283,
title = "Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence",
abstract = "Aldehyde dehydrogenase 1 (ALDH1) is a cancer stem cell (CSC) marker that is easily evaluable. The expression and clinical significance of ALDH1 in ipsilateral breast tumor recurrence (IBTR) has yet to be investigated. In the present study, the expression profile of ALDH1 and its correlation with prognosis in IBTR tissues was examined. Patients with IBTR from eight institutions were retrospectively enrolled in the study. Immunohistochemistry was used to examine ALDH1 expression patterns in the tissue specimens of primary cancers and IBTRs. ALDH1 expression levels were investigated in 182 IBTR tumors, which included cases of invasive carcinoma selected from 271 consecutive patients with IBTR. ALDH1 was expressed in 23{\%} of the IBTR tissue samples. The rate of concordant expression between primary cancer and IBTR tissues was 68{\%}. There was no significant association between disease-free survival (DFS) and ALDH1 expression levels in IBTR. IBTRs that expressed ALDH1 and Ki-67 had a poorer prognosis and this expression pattern was significantly associated with DFS (P=0.0073). The percentages of ALDH1 positive expression in each tissue subtype were as follows: Luminal A, 20{\%}; luminal B, 24{\%}; human epidermal growth factor 2 (HER2), 35{\%}; triple-negative, 21{\%}. There was a significant correlation between DFS and ALDH1 expression levels in HER2-type IBTR tissue specimens (P=0.034). In conclusion, it is possible that ALDH1 and Ki-67 expression levels may be useful for predicting prognosis in patients with HER2-type tumors.",
keywords = "Aldehyde dehydrogenase 1, Breast cancer, Cancer stem cell, Ipsilateral breast tumor recurrence, Prognostic factor",
author = "{The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society} and Tadahiko Shien and Takehiro Tanaka and Masahiko Tanabe and Yasuhiro Okumura and Norikazu Masuda and Atsushi Yoshida and Nobuyuki Arima and Yoshifumi Komoike and Satoru Tanaka and Takuji Iwase and Tetsuya Taguchi and Katsuhiko Nakatsukasa and Hideo Inaji and Makoto Ishitobi",
year = "2017",
month = "3",
day = "1",
doi = "10.3892/ol.2016.5538",
language = "English",
volume = "13",
pages = "1071--1077",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence

AU - The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

AU - Shien, Tadahiko

AU - Tanaka, Takehiro

AU - Tanabe, Masahiko

AU - Okumura, Yasuhiro

AU - Masuda, Norikazu

AU - Yoshida, Atsushi

AU - Arima, Nobuyuki

AU - Komoike, Yoshifumi

AU - Tanaka, Satoru

AU - Iwase, Takuji

AU - Taguchi, Tetsuya

AU - Nakatsukasa, Katsuhiko

AU - Inaji, Hideo

AU - Ishitobi, Makoto

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Aldehyde dehydrogenase 1 (ALDH1) is a cancer stem cell (CSC) marker that is easily evaluable. The expression and clinical significance of ALDH1 in ipsilateral breast tumor recurrence (IBTR) has yet to be investigated. In the present study, the expression profile of ALDH1 and its correlation with prognosis in IBTR tissues was examined. Patients with IBTR from eight institutions were retrospectively enrolled in the study. Immunohistochemistry was used to examine ALDH1 expression patterns in the tissue specimens of primary cancers and IBTRs. ALDH1 expression levels were investigated in 182 IBTR tumors, which included cases of invasive carcinoma selected from 271 consecutive patients with IBTR. ALDH1 was expressed in 23% of the IBTR tissue samples. The rate of concordant expression between primary cancer and IBTR tissues was 68%. There was no significant association between disease-free survival (DFS) and ALDH1 expression levels in IBTR. IBTRs that expressed ALDH1 and Ki-67 had a poorer prognosis and this expression pattern was significantly associated with DFS (P=0.0073). The percentages of ALDH1 positive expression in each tissue subtype were as follows: Luminal A, 20%; luminal B, 24%; human epidermal growth factor 2 (HER2), 35%; triple-negative, 21%. There was a significant correlation between DFS and ALDH1 expression levels in HER2-type IBTR tissue specimens (P=0.034). In conclusion, it is possible that ALDH1 and Ki-67 expression levels may be useful for predicting prognosis in patients with HER2-type tumors.

AB - Aldehyde dehydrogenase 1 (ALDH1) is a cancer stem cell (CSC) marker that is easily evaluable. The expression and clinical significance of ALDH1 in ipsilateral breast tumor recurrence (IBTR) has yet to be investigated. In the present study, the expression profile of ALDH1 and its correlation with prognosis in IBTR tissues was examined. Patients with IBTR from eight institutions were retrospectively enrolled in the study. Immunohistochemistry was used to examine ALDH1 expression patterns in the tissue specimens of primary cancers and IBTRs. ALDH1 expression levels were investigated in 182 IBTR tumors, which included cases of invasive carcinoma selected from 271 consecutive patients with IBTR. ALDH1 was expressed in 23% of the IBTR tissue samples. The rate of concordant expression between primary cancer and IBTR tissues was 68%. There was no significant association between disease-free survival (DFS) and ALDH1 expression levels in IBTR. IBTRs that expressed ALDH1 and Ki-67 had a poorer prognosis and this expression pattern was significantly associated with DFS (P=0.0073). The percentages of ALDH1 positive expression in each tissue subtype were as follows: Luminal A, 20%; luminal B, 24%; human epidermal growth factor 2 (HER2), 35%; triple-negative, 21%. There was a significant correlation between DFS and ALDH1 expression levels in HER2-type IBTR tissue specimens (P=0.034). In conclusion, it is possible that ALDH1 and Ki-67 expression levels may be useful for predicting prognosis in patients with HER2-type tumors.

KW - Aldehyde dehydrogenase 1

KW - Breast cancer

KW - Cancer stem cell

KW - Ipsilateral breast tumor recurrence

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=85011826950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011826950&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.5538

DO - 10.3892/ol.2016.5538

M3 - Article

VL - 13

SP - 1071

EP - 1077

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -